<DOC>
	<DOCNO>NCT01931241</DOCNO>
	<brief_summary>Preclinical data support hypothesis administration AHRO-001 reduce LDL cholesterol level , improve HDL function , finally , decrease atheromatous plaque burden .</brief_summary>
	<brief_title>Safety Study Bile Acid Treat Hypercholesteremia</brief_title>
	<detailed_description>4 sequential dosing cohort , cohort begin single dose ( SDD ) , single day exposure , follow one week multiple daily dosing ( MDD ) bid exposure , 4 day drug honeymoon , one week MDD utilizing tid exposure . Each subsequent cohort utilize SDD/MDD design , start SDD high prior SDD SDD significantly low prior tid MDD cohort complete , overall goal provide gradually increase dose exposure contingent satisfactory safety tolerability low dose previous group . Cohort 4 ( MDD ) utilize best dose determine Cohorts 1 , 2 &amp; 3 21 day . Estimated Duration Subject Participation : 8-9 week Under Protocol Amendment Version 5.0 , additional cohort , Cohort 5 , concomitantly enroll 48 volunteer randomize receive either AHRO-001 placebo . Volunteers include study may either currently receive receive statin treatment . The 48 volunteer Cohort 5 thus allocate 3 treatment group 16 volunteer enrol per group : Group A : AHRO-001 alone Group B : Statin + AHRO-001 Group C : Placebo SUBJECT POPULATION : Healthy volunteer , male &amp; infertile female , asymptomatic mild moderate hypercholesterolemia</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Key Males OR infertile Females 1870 year age , inclusive Asymptomatic mild moderate hypercholesterolemia , ( LDL =110220 mg/dL ) Cohort 5 : statin stable statin dose meeting LDL &gt; 110 mg % Key Exclusion criterion Fasting triglyceride &lt; 90 &gt; 250 mg/dl ( &lt; 0.85 mmol/l &gt; 2.8 mmol/l ) Body Mass Index ( BMI ) &lt; 18 &gt; 34 kg/m2 Diabetes mellitus ( FBS &gt; 125 mg % ( &gt; 6.94 mmol/l ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; ULN Serum creatinine &gt; ULN gender Hemoglobin &lt; 11.5 g/dL Female volunteer childbearing potential History cancer past 5 year Any disease require medication Use investigational medication past 3 month Positive result illegal drug , HBsAg , HBsAb , HCV HIV Cohort 5 : Prescription lipid lower medication statin past 4 wks Cohort 5 : History gastrointestinal tract surgical resection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>atherosclerosis</keyword>
	<keyword>atherosclerotic heart disease</keyword>
	<keyword>hypercholesteremia</keyword>
	<keyword>atherosclerotic plaque</keyword>
	<keyword>hyperlipidemia</keyword>
</DOC>